Cite
HARVARD Citation
Abid, M. et al. (2018). Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?. Hematological oncology. 36 (1), pp. 320-323. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Abid, M. et al. (2018). Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?. Hematological oncology. 36 (1), pp. 320-323. [Online].